A New Star in Cancer Therapy (OTC BB:ADXS)
The Market Financial
Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money — Advaxis (OTC BB:ADXS) is a beginner in the biotech oncology world, but has recently shown some reason to think they stand out from the pack. ADXS might be one of these hidden gems, following DNDN or ONTY. The Oncology sector has been a good investment so far and has provided huge reward this year. There is no doubt that Cancer therapy companies should again be in the Spotlight for the next years.
Advaxis is using Listeria monocytogenes bacteria as a vector to destroy solid tumors in patients. There is no other biotech company that is using this modality to treat cancer patients. It is not some newly discovered drug, but based on a biological entity that has been studied for over a hundred years and whose actions have been well documented if not totally understood. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
The full special report on the company appears today at http://www.themarketfinancial.com/a-new-star-in-cancer-therapy/1126
Disclosure: Author is Long ADXS
MiV Investments Inc. can be found at TheMarketFinancial.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews, premium services and other unique content including expert stock analysis from a variety of accredited staff and authors. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.TheMarketFinancial.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. TheMarketFinancial.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- President, CEO, Publisher
- MIV Investments Inc.
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.